临床试验登记· Fred Hutchinson Cancer Center · ClinicalTrials.gov·· 10 小时前评分29
Tacabrutideg联合Sonrotoclax并依据应答加用Obinutuzumab治疗CLL/SLL
Tacabrutideg and Sonrotoclax, With Response-Guided Obinutuzumab, for the Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
导读
2期试验NCT07887061登记Tacabrutideg联合Sonrotoclax治疗CLL/SLL。该试验由Fred Hutchinson Cancer Center申办，并依据应答加用Obinutuzumab，计划入组30人。拟评估联合治疗效果，目前尚未招募，计划2027-01-01启动。
来源：临床试验登记 · clinicaltrials.gov